See the DrugPatentWatch profile for Uzedy
Uzedy was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2023, for the treatment of chronic immune thrombocytopenia (ITP) in adults [1].
What is Uzedy used to treat?
Uzedy, also known as human interleukin-11 (hIL-11), is a thrombopoietin receptor agonist. It is indicated for adults with chronic immune thrombocytopenia (ITP) [1]. ITP is a bleeding disorder in which the immune system destroys platelets [2].
How does Uzedy work?
Uzedy stimulates the production of platelets by binding to the thrombopoietin receptor [1]. By increasing platelet counts, it helps to reduce the risk of bleeding in patients with chronic ITP [2].
When does Uzedy's patent expire?
Patent information for Uzedy can be accessed through DrugPatentWatch.com [3]. For specific patent expiry dates, it is recommended to consult detailed patent databases [3].
What are the alternatives to Uzedy for ITP treatment?
Other treatment options for chronic ITP include corticosteroids, intravenous immunoglobulin (IVIg), and splenectomy [2]. Thrombopoietin receptor agonists (TPO-RAs) such as romiplostim and eltrombopag are also used for ITP [4]. Uzedy is a novel TPO-RA that offers an alternative mechanism of action within this class [1].
What clinical data supports Uzedy's approval?
Uzedy's approval was based on data from two Phase 3 clinical trials, Yosemite I and Yosemite II [1]. These studies demonstrated that Uzedy was effective in increasing and maintaining platelet counts in adults with chronic ITP [1].
Who manufactures Uzedy?
Uzedy is manufactured by AbbVie [1].
What are the potential side effects of Uzedy?
Common side effects of Uzedy include upper respiratory tract infections, headache, and injection site reactions [1]. More serious risks can include thromboembolic complications, such as blood clots [1]. Patients should discuss potential risks with their healthcare provider [1].
***
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/uzedy-tbo-f
[2] https://www.nhlbi.nih.gov/health/immune-thrombocytopenia
[3] https://drugpatentwatch.com/
[4] https://www.uptodate.com/contents/overview-of-treatment-of-immune-thrombocytopenia-in-adults